Literature DB >> 16442206

Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: results of a retrospective multi-center study.

Dirk Rades1, Jochen Walz, Lukas J A Stalpers, Theo Veninga, Rainer Schulte, Nermina Obralic, Ingeborg Wildfang, Rita Engenhart-Cabilic, Peter J Hoskin, Steven E Schild.   

Abstract

OBJECTIVE: For MSCC treatment, a short treatment time is desirable, especially if survival prognosis is poor. Survival depends on the primary tumor, extent of disease, performance status, ambulatory status, and the number of involved vertebrae. These factors may help to define the appropriate regimen for the individual patient. Our study compares short-course (1 x 8 Gy, 5 x 4 Gy) and long-course RT (10 x 3 Gy, 15 x 2.5 Gy, 20 x 2 Gy) for functional outcome in MSCC patients with renal cell carcinoma.
METHODS: The following potential prognostic factors for functional outcome were retrospectively investigated: age, performance status, involved vertebra, ambulatory status, time of developing motor deficits before RT, radiation schedule (short-course RT, n=37; long-course RT, n=50).
RESULTS: Eighty-seven patients were included in this retrospective study, 25 patients (29%) showed improvement of motor function, 52 patients (60%) no change, 10 patients (11%) deterioration. 25% of non-ambulatory patients became ambulatory after RT. Functional outcome was affected by the time of developing motor deficits before RT (p<0.001). The RT schedule had no significant impact (p=0.91). In the short-course RT sub-group, functional outcome was similar for 1 x 8 Gy and 5 x 4 Gy (p=0.99).
CONCLUSION: Short-course and long-course RT appear similarly active for MSCC in patients with renal cell carcinoma. Short-course RT appears preferable, as it is means less patient discomfort. Because 1 x 8 Gy and 5 x 4 Gy were comparably effective, 1 x 8 Gy may be suggested the best actual choice.

Entities:  

Mesh:

Year:  2005        PMID: 16442206     DOI: 10.1016/j.eururo.2005.11.004

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.

Authors:  Katja Freundt; Thekla Meyners; Amira Bajrovic; Hiba Basic; Johann H Karstens; Irenaeus A Adamietz; Volker Rudat; Steven E Schild; Juergen Dunst; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

2.  Stereotactic radiosurgery compared with external radiation therapy as a primary treatment in spine metastasis from renal cell carcinoma: a multicenter, matched-pair study.

Authors:  Seil Sohn; Chun Kee Chung; Moon Jun Sohn; Ung-Kyu Chang; Sung Hwan Kim; Jinhee Kim; Eunjung Park
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

Review 3.  The role of radiotherapy for metastatic epidural spinal cord compression.

Authors:  Dirk Rades; Janet L Abrahm
Journal:  Nat Rev Clin Oncol       Date:  2010-08-31       Impact factor: 66.675

4.  A new prognostic factor for the survival of patients with renal cell carcinoma developing metastatic spinal cord compression.

Authors:  D Rades; A Weber; T Bartscht; A Bajrovic; J H Karstens; S E Schild
Journal:  Strahlenther Onkol       Date:  2014-02-18       Impact factor: 3.621

Review 5.  Comparison of Short-Course Radiotherapy Versus Long-Course Radiotherapy for Treatment of Metastatic Spinal Cord Compression: A Systematic Review and Meta-Analysis.

Authors:  Song Qu; Hui-Ling Meng; Zhong-Guo Liang; Xiao-Dong Zhu; Ling Li; Ling-Xiao Chen; Zhi-Rui Zhou
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

6.  Outcomes of patients with spinal metastases from renal cell carcinoma treated with conventionally-fractionated external beam radiation therapy.

Authors:  Chia Ching Lee; Jeremy Chee Seong Tey; Timothy Cheo; Chau Hung Lee; Alvin Wong; Naresh Kumar; Balamurugan Vellayappan
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.